Ohlsentherkildsen5276

Z Iurium Wiki

Verze z 19. 11. 2024, 16:45, kterou vytvořil Ohlsentherkildsen5276 (diskuse | příspěvky) (Založena nová stránka s textem „Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint inhibitor, are both considered to cause hepatotoxicity with different pathophys…“)
(rozdíl) ← Starší verze | zobrazit aktuální verzi (rozdíl) | Novější verze → (rozdíl)

Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint inhibitor, are both considered to cause hepatotoxicity with different pathophysiology. We report a case in which a patient died of severe hepatotoxicity who was presumed to have been caused by the administration of nivolumab followed by pazopanib for metastatic renal cell carcinoma.

A 74-year-old male with metastatic renal cell carcinoma was treated with nivolumab as a third-line treatment. However, nivolumab was subsequently discontinued, as it caused severe thyroiditis. About 2months after the final dose of nivolumab was administered, pazopanib was initiated as a fourth-line treatment. The patient suffered from lethal hepatic failure and died 18days after the initiation of pazopanib treatment. An autopsy revealed that CD8-positive lymphocytes had infiltrated the thyroid gland and liver.

The patient was considered to have died of severe hepatic failure due to the aggravation of mild nivolumab-induced immune-related hepatitis by pazopanib.

The patient was considered to have died of severe hepatic failure due to the aggravation of mild nivolumab-induced immune-related hepatitis by pazopanib.

Several types of cancers are reported to induce secondary immune thrombocytopenia resembling immune thrombocytopenic purpura-like syndrome. However, renal cell carcinoma-induced immune thrombocytopenic purpura is an extremely rare phenomenon.

A 73-year-old male with right renal tumor and multiple enlarged lymph nodes presented severe thrombocytopenia, without bone or hepatic metastasis. Although platelet transfusion and high-dose immunoglobulin treatment were refractory, surgical resection of the tumor and lymph nodes promptly improved thrombocytopenia. After recurrence, he presented thrombocytopenia again. Tyrosine kinase inhibitor treatment was ceased due to uncontrollable hemorrhagic gastric ulcer. The patient eventually died of cancer 4months after surgery. Flow cytometry analysis revealed the presence of integrin glycoprotein IIb/IIIa, which is a fibronectin/fibrinogen receptor on platelets and as an antigen in immune thrombocytopenic purpura.

To the best of our knowledge, this is the first reported case of renal cell carcinoma-induced immune thrombocytopenic purpura that demonstrates the presence of platelet-autoantibody glycoprotein IIb/IIIa.

To the best of our knowledge, this is the first reported case of renal cell carcinoma-induced immune thrombocytopenic purpura that demonstrates the presence of platelet-autoantibody glycoprotein IIb/IIIa.Magnetically induced catalysis using magnetic nanoparticles (MagNPs) as heating agents is a new efficient method to perform reactions at high temperatures. However, the main limitation is the lack of stability of the catalysts operating in such harsh conditions. Normally, above 500 °C, significant sintering of MagNPs takes place. Here we present encapsulated magnetic FeCo and Co NPs in carbon (Co@C and FeCo@C) as an ultrastable heating material suitable for high-temperature magnetic catalysis. Indeed, FeCo@C or a mixture of FeCo@CCo@C (21) decorated with Ni or Pt-Sn showed good stability in terms of temperature and catalytic performances. In addition, consistent conversions and selectivities regarding conventional heating were observed for CO2 methanation (Sabatier reaction), propane dehydrogenation (PDH), and propane dry reforming (PDR). Thus, the encapsulation of MagNPs in carbon constitutes a major advance in the development of stable catalysts for high-temperature magnetically induced catalysis.The unique attributes of surface enhanced Raman spectroscopy (SERS) make it well suited to address the challenges associated with portable diagnostics. compound library inhibitor However, despite the remarkable progress in this field, where the instrumentation has made great strides forward providing a route to the miniaturization of sensing devices, to date producing three-dimensional low-cost SERS substrates which simultaneously fulfill the multitude of criteria of high sensitivity, reproducibility, tunability, multiplexity, and integratability for rapid sensing has not yet been accomplished. Successful implementation of SERS requires readily fine-tuned nanostructures, which create a high enhancement. Here, an advanced electrofluidynamic patterning (EFDP) technique enables rapid fabrication of SERS active topographic morphologies with high throughput and at a nanoresolution via the spatial and lateral modulation of the dielectric discontinuity due to the high electric field generated across the polymer nanofilm and air gap. The subsequent formation of displacement charges within the nanofilm by coupling to the electric field yield a destabilizing electrostatic pressure and amplification of EFDP instabilities enabling the controllable pattern formation. The top of each gold coated EFDP fabricated pillar generates controllable high SERS enhancement by coupling of surface plasmon modes on top of the pillar, with each nanostructure acting as an individual sensing unit. The absolute enhancement factor depends on the topology as well as the tunable dimensions of the nanostructured units, and these are optimized in the design and engineering of the dedicated EFDP apparatus for reproducible, low-cost fabrication of the three-dimensional nanoarchitectures on macrosurfaces, rendering them for easy integration in further lab-on-a-chip devices. This unique combination of nanomaterials and nanospectroscopic systems lay the platform for a variety of applications in chemical and biological sensing.A study was conducted to evaluate the effects of intake management and ionophore inclusion on diet utilization under managed intake conditions in beef cattle. Two experiments utilized common diets fed at 120% (H) or 80% (L) of maintenance with either 0 or 200 mg/d monensin in a factorial arrangement. Forty cows were fed for 56 d (Exp. 1) to evaluate effects on diet utilization and energy retention; diets were fed to 16 ruminally cannulated steers (Exp. 2) to determine effects on digestion, energy value, and ruminal fermentation. Cows fed H had greater body weight (BW) gain (P 0.15) but did reduce passage rate (P less then 0.03). Monensin lowered (P less then 0.01) acetatepropionate ratio and increased (P less then 0.05) ruminal pH. Monensin did not alter feed required for maintenance; however, limit-feeding reduced apparent daily maintenance requirement to 62.85 kcal/kg BW0.75, a 26% reduction from model-predicted values.

Autoři článku: Ohlsentherkildsen5276 (Damgaard Ballard)